The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors ...

If you're an income investor or retiree, there's a high likelihood that Business Development Companies make up a sizable portion of your portfolio. As an income investor myself, but not yet near the ...

NAV Development and Dividend Policy NAXS has demonstrated a commitment to shareholder returns through its dividend policy, which targets distribution of 50-75% of profit after tax. For the current ...

Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 ...

Aker ASA (OB:AKER) presented its second quarter and half-year 2025 results on July 16, highlighting solid financial performance despite challenging market conditions. The Norwegian industrial ...

NAXS Nordic Access Buyout Fund AB (NASDAQ:NAXS) released its Q2 2025 presentation on August 5, 2025, revealing a quarterly decline in net asset value (NAV) amid challenging market conditions. The ...